Please login to the form below

Not currently logged in
Email:
Password:

Medivir buys BioPhausia

Medivir acquires BioPhausia in €62m deal as it looks to market new hepatitis C drug

Swedish company Medivir, which develops pharmaceuticals against infectious diseases caused by viruses, is to acquire specialty pharmaceutical company BioPhausia for SEK565 million (€62m).

Medivir says that the acquisition would provide it with a well-established commercial platform from which to launch its hepatitis C drug TMC435, which should be introduced on to the market by 2013.

Ron Long, chief executive of Medivir, said: "The task in hand for us is to put ourselves in a position where we can educate the market about the virtues and advantages of TMC435.”

Under the terms of the deal, Medivir is offering a mixture of cash and new shares.

13th April 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics